This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Interventions
Bendamustine intravenous infusion was compared with oral chlorambucil, as initial chemotherapy. All patients received either drug for three 28-day treatment cycles. Those who remained progression free for 12 months, on chlorambucil, continued on chlorambucil, if they later progressed, ad infinitum. Half of all other patients who progressed received fludarabine plus cyclophosphamide, and the other half received best supportive care.
Location/setting
UK/out-patient care.
Methods

Analytical approach:
A semi-Markov cohort model was used to simulate the natural history and treatment of chronic lymphocytic leukaemia, over the lifetime of each patient. Disease progression was captured using the health states of partial response, stable disease, complete response, progressive disease, best supportive care, and death. The authors stated that the perspective was that of the UK NHS.
Effectiveness data:
The primary effectiveness data were from a 2009 open-label randomised controlled trial of bendamustine, compared with chlorambucil, as a first treatment for chronic lymphocytic leukaemia. This was the only trial of bendamustine for chronic lymphocytic leukaemia that was identified by a systematic review conducted for the National Institute for Health and Clinical Excellence (NICE) in 2011. The primary measures of effectiveness were the odds ratio of response, and progression-free survival. Time-to-event regressions were used to fit survival curves, to extrapolate the trial data. Regression results and their coefficients were presented in graphs and tables, with covariance measures.
Monetary benefit and utility valuations:
The utility values for patients initially and those with stable disease were mapped from European Organisation for Research and Treatment of Cancer (EORTC)-C30 questionnaire results, from the trial patients, to the EQ-5D, using a published algorithm. Utility increments and decrements, for state changes and adverse events, were from a published study of patients with chronic lymphocytic leukaemia.
